FR2822475B1 - Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments - Google Patents

Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments

Info

Publication number
FR2822475B1
FR2822475B1 FR0203459A FR0203459A FR2822475B1 FR 2822475 B1 FR2822475 B1 FR 2822475B1 FR 0203459 A FR0203459 A FR 0203459A FR 0203459 A FR0203459 A FR 0203459A FR 2822475 B1 FR2822475 B1 FR 2822475B1
Authority
FR
France
Prior art keywords
tumor
medicaments
apoptosis
phenomena
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0203459A
Other languages
English (en)
Other versions
FR2822475A1 (fr
Inventor
Adam Telerman
Robert Amson
Marcel Tuijnder
Laurent Susini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MOLECULAR ENGINES LAB
Original Assignee
MOLECULAR ENGINES LAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MOLECULAR ENGINES LAB filed Critical MOLECULAR ENGINES LAB
Priority to FR0203459A priority Critical patent/FR2822475B1/fr
Publication of FR2822475A1 publication Critical patent/FR2822475A1/fr
Application granted granted Critical
Publication of FR2822475B1 publication Critical patent/FR2822475B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR0203459A 2002-03-20 2002-03-20 Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments Expired - Fee Related FR2822475B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0203459A FR2822475B1 (fr) 2002-03-20 2002-03-20 Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0203459A FR2822475B1 (fr) 2002-03-20 2002-03-20 Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments

Publications (2)

Publication Number Publication Date
FR2822475A1 FR2822475A1 (fr) 2002-09-27
FR2822475B1 true FR2822475B1 (fr) 2005-12-30

Family

ID=8871502

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0203459A Expired - Fee Related FR2822475B1 (fr) 2002-03-20 2002-03-20 Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments

Country Status (1)

Country Link
FR (1) FR2822475B1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087372A2 (fr) * 2002-04-12 2003-10-23 Molecular Engines Laboratories Facteur de croissance derive d’hepatome et son utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012881A2 (fr) * 1992-12-02 1994-06-09 Hochstrasser Denis F PROCEDE DE DETECTION DE CELLULES EN CROISSANCE A L'AIDE DE PROTEINE TUMORALE p21 REGULEE PAR TRADUCTION
FR2782085B1 (fr) * 1998-08-05 2002-12-13 Fond Jean Dausset Ceph Genes impliques dans les voies moleculaires de la suppression tumorale et/ou la resistance aux virus
FR2820757A1 (fr) * 2001-02-13 2002-08-16 Molecular Engines Lab Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicamments

Also Published As

Publication number Publication date
FR2822475A1 (fr) 2002-09-27

Similar Documents

Publication Publication Date Title
DK1663287T3 (da) Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
CY2016039I2 (el) Χιμαιρικες πρωτεϊνες παραγοντα πηξης για την αγωγη αιμοστατικων ασθενειων
DK1196163T3 (da) Farmaceutiske sammensætninger til behandling af insulinresistens
IL230815A (en) Dictopyrazine Compounds, Pharmaceuticals Containing Them and Use in the Treatment of T-Mediated Diseases
NO20053920D0 (no) Preparat for og behandling av demyelineringssykdommer og paralyse ved administrering av remyelineringsmidler.
WO2004016225A8 (fr) Compositions et methodes de diagnostic et de traitement des tumeurs
WO2004045516A9 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
IL190478A0 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
MA28604B1 (fr) Derives de piperazine et leur utilisation dans la lutte contre les organismes nuisibles
DE602004008262D1 (de) Designs von implantierbaren medizinischen leitungen
DK1638589T3 (da) Kombinationsterapi med glatirameracetat og mitoxantron til behandling af multipel sklerose
WO2004060270A8 (fr) Compositions et methodes pour diagnostiquer et traiter des tumeurs
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
ATE479437T1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
EP1765330A4 (fr) Derives de pyranoindole et utilisation de ceux-ci pour le traitement d'une maladie ou d'une infection provoquee par le virus de l'hepatite c
ZA200500882B (en) Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis of treatment or liver disorders and epithelial cancer
HK1095036A1 (en) Virus therapeutic drug
WO2005003154A8 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
EP1765832B8 (fr) Nouveaux composes oxabispidine et leur utilisation dans le traitement des arythmies cardiaques
AU2003287145A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
FR2870846B1 (fr) Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
FR2782085B1 (fr) Genes impliques dans les voies moleculaires de la suppression tumorale et/ou la resistance aux virus
FR2822475B1 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
AU2003299962A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis

Legal Events

Date Code Title Description
ST Notification of lapse
D3 Decision to revoke the decision of lapse
RN Application for restoration
ST Notification of lapse

Effective date: 20081031